Zhitong Finance App News, Shanghai Pharmaceutical (601607.SH) issued an announcement. Recently, Shangyao Dongying (Jiangsu) Pharmaceutical Co., Ltd. (hereinafter referred to as “Shangyao Dongying”), a subsidiary of the company, received the “Drug Registration Certificate” (certificate number: 2026S03379) issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”) for injectable isaconazole sulfate (hereinafter referred to as “this drug”). Injectable isaconazole sulfate is suitable for the treatment of the following infections in adults and children aged 1 year and above: aggressive aspergillosis, invasive furuncle mildew.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.